21 October 2025NewsAmericasMarisa Woutersen

Data and delivery: Inside AI's inventorship dilemma

Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Top pharma, biotech, and medtech experts gather at LSPN Fall

21 October 2025 LSIPR is gearing up for the 5th annual LSPN North America Fall Conference, starting October 21, in San Francisco, California.

Americas

Protect early, partner wisely: In-house tips for medtech startups

15 October 2025 In-house IP director at RefleXion talks about protecting complex medtech, why startups can't afford to cut corners on early decisions, and when to employ outside expertise.

Big Pharma

Why AI drug discovery has an IP problem and what can be done

6 October 2025 Can AI tools raise the bar for inventiveness? And when algorithms become as productive as living systems, will they make their own outputs unpatentable? Industry experts unpick AI drug discovery’s biggest issues.

More features

Weil continues expansion with top trade secrets litigator

Top pharma, biotech, and medtech experts gather at LSPN Fall

Mitsubishi Tanabe doubles down on Radicava protection

‘All it takes is a post on Truth Social’: Is this patent reform's moment?

Novartis fails to block repackaged imports of blockbuster treatment

Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’

Protect early, partner wisely: In-house tips for medtech startups

Latham scoops Simmons partner for its London office

Data and delivery: Inside AI's inventorship dilemma

More on this story

Editor's picks

Editor's picks

More features